| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Biochemistry & Biophysics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 [A. B., U. M., L. M., M. D.]; and The Wistar Institute, Philadelphia, Pennsylvania 19104, [U. R., M. H.]
The epidermal growth factor (EGF) receptor in two colon carcinoma lines and in one vulval carcinoma line tested contains carbohydrate determinants that are recognized by monoclonal antibodies to tumor-associated antigens. These antibodies are directed to sialylated Lea and to difucosylated structures of the Y type. Cell lines which react with these antibodies express these antigens on their surface glycolipids and glycoproteins, including the EGF receptor. These unusual carbohydrates are absent in EGF receptors from normal untransformed cells, and from tumor cells which do not express these specific antigens. Although EGF receptor represents only 0.1–2% of total plasma membrane proteins of antigen-positive carcinomas, it accounts for 20–80% of total protein-associated sialylated Lea/Y type of nonsecreted carbohydrates present in these cells. The results of cell-binding, immunoprecipitation, and Western blot analyses of the antigen-positive carcinomas indicate that sialylated Lea/Y type of antigenicity is intrinsic to the EGF receptors of these cells, and that the antigen is present in receptors from both over-expressing and normal-expressing carcinomas.
1 Supported by NIH Research Grants CA-43787 [M. D.]. HD-17896 [M. D.], CA-25874 [M. H.], and by a grant (RO-619) [U. R.] from Deutsche Forschungsgemeinschaft.
2 To whom requests for reprints should be addressed.
Received 9/11/86. Revised 1/27/87. Accepted 2/19/87.
This article has been cited by other articles:
|
|
 |
|
  H. Farhan, C. Schuster, M. Klinger, E. Weisz, G. Waxenecker, M. Schuster, V. Sexl, G. C. Mudde, M. Freissmuth, and R. Kircheis Inhibition of Xenograft Tumor Growth and Down-Regulation of ErbB Receptors by an Antibody Directed against Lewis Y Antigen J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1459 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. T. Lee, A. J. Mountain, M. P. Kelly, C. Hall, A. Rigopoulos, T. G. Johns, F. E. Smyth, M. W. Brechbiel, E. C. Nice, A. W. Burgess, et al. Enhanced Efficacy of Radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478 Clin. Cancer Res., October 1, 2005; 11(19): 7080s - 7086s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Bhowmick, Z. Zhuang, S. D. Wait, and R. J. Weil A Functional Polymorphism in the EGF Gene Is Found with Increased Frequency in Glioblastoma Multiforme Patients and Is Associated with More Aggressive Disease Cancer Res., February 15, 2004; 64(4): 1220 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Klinger, H. Farhan, H. Just, H. Drobny, G. Himmler, H. Loibner, G. C. Mudde, M. Freissmuth, and V. Sexl Antibodies Directed against Lewis-Y Antigen Inhibit Signaling of Lewis-Y Modified ErbB Receptors Cancer Res., February 1, 2004; 64(3): 1087 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Rodeck, M. Jost, J. DuHadaway, C. Kari, P. J. Jensen, B. Risse, and D. L. Ewert Regulation of Bcl-xL expression in human keratinocytes by cell-substratum adhesion and the epidermal growth factor receptor PNAS, May 13, 1997; 94(10): 5067 - 5072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U Rodeck, M Jost, C Kari, D. Shih, R. Lavker, D. Ewert, and P. Jensen EGF-R dependent regulation of keratinocyte survival J. Cell Sci., January 1, 1997; 110(2): 113 - 121. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
